Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sorafenib (BAY 43-9006) plus weekly gemcitabine in metastatic renal cell carcinoma
2006-000231-95Phase 2Active
- Sponsor
- Innovative Sensor Technology IST AG
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib and gemcitabine in renal cell carcinoma (RCC), sponsored by Innovative Sensor Technology IST AG. Primary endpoint: clinical benefit response. Started Jun 2006; status: active.
02
Drugs
sorafenibgemcitabine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2006-000231-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000231-95.